期刊文献+

男男性行为人群艾滋病暴露前预防用药临床试验队列保持力分析 被引量:11

Cohort retention in HIV pre-exposure prophylaxis clinical trial among men who have sex with men
下载PDF
导出
摘要 目的:了解男男性行为者(men who have sex with men,MSM)在艾滋病暴露前预防用药(pre-exposure prophylaxis,Pr EP)临床试验中的队列保持力及其影响因素。方法:采用非概率抽样法招募并筛选出297名MSM进入研究,随机分为每日用药组、高危行为前后用药组和空白对照组,每3月进行临床随访和问卷调查。利用Kaplan-Meier估计的生存曲线描述不同试验组的累积队列保持率,单因素和多因素Cox回归用于分析队列保持的影响因素。结果:43.1%(128/297)的MSM完成了本研究的随访,队列平均保持时间(5.85±3.99)月。高危行为前后用药组相对空白对照组(AHR=0.62,95%CI=0.42-0.91)、年龄30岁以上(AHR=0.65,95%CI=0.47-0.90)的MSM有更高的队列保持力。结论:本研究中MSM人群Pr EP临床试验队列保持力不高,在后期研究中需加强空白对照组和低年龄MSM的队列管理,以提高临床试验的队列保持力。 Objective:To explore cohort retention and associated factors in HIV pre-exposure prophylaxis(PrEP) clinical trial among men who have sex with men(MSM). Methods:Totally 297 MSM were enrolled by non-probability sampling methods and then assigned to daily dose,intermittent dose and blank control arms randomly. Clinical follow-up and questionnaire were carried out every 3 months. Cumulative cohort retention rates of different arms were described by Kaplan-Meier estimation. Univariate and multivariate Cox regression were used to analyze associated factors of cohort retention. Results :43.1%(128/297) of participants completed the fol- low-up in this study and the mean retention time was (5.85 ± 3.99) months. Those who were in intermittent dose arm(AHR=0.62, 95%CI=0.42 to 0.91 ) and older than 30 years(AHR=0.65,95%CI=0.47 to 0.90) showed higher cohort retention. Conclusion :The cohort retention of PrEP clinical trial among MSM in this study is not high. Effective measures should be taken to improve the cohort retention of MSM in blank control arm and younger age.
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2014年第11期1573-1577,共5页 Journal of Chongqing Medical University
基金 国家科技重大专项资助项目(编号:2012ZX10001-007)
关键词 男男性行为者 艾滋病毒 暴露前预防用药 队列保持 men who have sex with men human immunodeficiency virus pre-exposure prophylaxis cohort retention
  • 相关文献

参考文献17

  • 1中华人民共和国卫生部,联合国艾滋病规划署,世界卫生组织2011年中国艾滋病疫情估计[c].北京,2011. 被引量:1
  • 2李希光,顾小琛,景军,等.针对我国男同性恋(MSM)群体艾滋病传播的网络干预研究--以“中盖艾滋病项目”为例[A].2012年度中国健康传播大会优秀论文集[C],清华大学国际传播研究中心,2012. 被引量:1
  • 3中华人民共和国卫生部,联合国艾滋病规划署,世界卫生组织.2009年中国艾滋病疫情估计工作报告[c].北京,2010. 被引量:1
  • 4Liu AY, Kittredge PV,Vittinghoff E,et al.Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisex- ual men[J].J Acquit Immune Defic Syndr, 2008,47 (2) : 241-247. 被引量:1
  • 5Abdool Karim Q,Abdool Karim SS, Frohlieh JA, et al.Effectiveness and safety of tenofovir gel, an antiretroviral mierobieide, for the preven- tion of HIV infection in women [J].Seienee, 2010,329 (5996) : 1168- 1174. 被引量:1
  • 6Grant RM, Lama JR,Anderson PL, et al.Preexposure ehemoprophy- laxis for HIV prevention in men who have sex with men[J].N Engl J Med, 2010,363 (27) : 2587-2599. 被引量:1
  • 7Baeten JM,Donnell D, Ndase P, et al.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women[J].N Engl J Med, 2012,367(5) :399-410. 被引量:1
  • 8贾元元,钟晓妮,张燕,彭斌,黄文祥,梁浩,邹云锋,戴江红,罗锦昆,彭鸿斌,刘倩萍,宋本莉,黄爱龙.艾滋病暴露前用药优先干预人群筛选研究[J].重庆医科大学学报,2011,36(10):1225-1228. 被引量:5
  • 9张燕,钟晓妮,彭斌,黄文祥,黄爱龙.男男性行为人群艾滋病暴露前预防用药临床试验队列保持力及预测因子分析[J].第三军医大学学报,2013,35(22):2469-2472. 被引量:4
  • 10Khosropour CM, Johnson BA, Ricca AV, et al.Enhancing retention of an Interuet-based cohort study of men who have sex with men (MSM) via text messaging:randomized controlled trial[J].J Med Inter- net Res,2013,15(8) :e194. 被引量:1

二级参考文献48

共引文献43

同被引文献74

  • 1刘靖,王林.抗逆转录病毒药物的肝毒性[J].国外医学(药学分册),2005,32(5):335-338. 被引量:10
  • 2COHEN M S, CHEN Y Q, MCCAULEY M, et al. Prevention of HIV-1 infection with early antiretroviral therapy[J]. N Engl J Med, 2011, 365 (6): 493 -505. 被引量:1
  • 3Insight Start Study Group, LUNDGREN J D, BABIKER A G, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection E J ]. N Engl J Med, 2015, 373(9) : 795-807. 被引量:1
  • 4US Pubhc Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 a clinical practice guideline[ M/OL]. (2014-05- 14) [ 2016-01-05 ]. http://www, cdc. gov/hiv/pdf/ prepguidelines2014, pdf. 被引量:1
  • 5World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV[J/OLI. (2015) [2016-01-05]. http://www. who. int/hiv/pub/guidelines/earlyrelease-arv/en/. 被引量:1
  • 6European AIDS Clinical Society. EACS guidelines 8.0 [J/OL]. (2015-10) [2016-01-05]. http:// www. eacsociety, org/guidelines/eacs-guidelines/ eacs-guidelines, html. 被引量:1
  • 7OKWUNDU C I, UTHMAN O A, OKOROMAH C A. Antiretroviral pre-exposure prophylaxis (PREP) for preventing HIV in high-risk individuals [ J ]. Cochrane Database Syst Rev, 2012, 11 (7) : CD007189. 被引量:1
  • 8GRANT R M, LAMA J R, ANDERSON P L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men [ J ]. N Engl J Med, 2010, 363(27) : 2587-2599. 被引量:1
  • 9THIGPEN M C, KEBAABETSWE P M, PAXTON L A, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana[ J]. N Engl J Meal, 2012, 367(5) : 423-434. 被引量:1
  • 10BAETEN J M, DONNELL D, NDASE P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women [ J ]. N Engl J Meal, 2012, 367(5): 399-410. 被引量:1

引证文献11

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部